Resource Summary

Clinical Question:
In patients with type 2 diabetes^ do sodium-glucose co-transporter 2 (SGLT2) inhibitors affect mortality or cardiovascular disease (CVD)?
Bottom Line:
In diabetic patients at high-risk for CVD^ empagliflozin reduces mortality for 1 in 39 patients at ~3 years (compared to placebo)^ while canagliflozin and empagliflozin both reduce CVD death^ non-fatal myocardial infarction (MI)^ and stroke for ~1 in 60 patients. Both medications increased genital infections for ~1 in 6-22 and canagliflozin increased volume depletion (1 in 14-38) and amputations (1 in 96). Cost may limit use.

https://www.acfp.ca/tools-for-practice/

Publication Date: 2017-10-30
Last Updated on PCR: 2017-11-04 12:53:16